SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jemal A, Siegal R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-249.
  • 2
    Waggoner SE. Cervical cancer. Lancet. 2003; 361: 2217-2225.
  • 3
    National Cancer Institute. Cervical Cancer (PDQ): Treatment. Bethesda, MD: National Cancer Institute; 2005. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/cervical/HealthProfessional/page4. Accessed May 2011.
  • 4
    Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database Syst Rev. 2010;( 1): CD008285.
  • 5
    Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB recurrent or persistent squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2004; 22: 3113-3119.
  • 6
    Long HJ, Bundy BN, Grendys EC, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2005; 23: 4626-4633.
  • 7
    Monk BJ, Sill M, McMeekin DS, et al. A randomized phase III trial of 4 cisplatin (CIS) containing doublet combinations in stage IVB, recurrent or persistent cervical carcinoma: a Gynecologic Oncology Group (GOG) study J Clin Oncol. 2008; 26( May 20 suppl). Abstract LBA5504.
  • 8
    Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, Roman LD. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2009; 27: 1069-1074.
  • 9
    Goncalves A, Fabbro M, Lhomme C, et al. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol. 2008; 108: 42-46.
  • 10
    Ingham PW, McMahon AP. Hedgehog signaling in animal development: paradigms and principles. Genes Dev. 2001; 15: 3059-3087.
  • 11
    Hooper JE, Scott MP. Communicating with hedgehogs. Nat Rev Mol Cell Biol. 2005; 6: 306-317.
  • 12
    Caro I, Low JA. The role of the hedgehog signaling pathway in the development of basal cell carcinoma and opportunities for treatment. Clin Cancer Res. 2010; 16: 3335-3339.
  • 13
    Liao X, Siu MKY, Au CWH, et al. Aberrant activation of hedgehog signaling pathway in ovarian cancers: effect on prognosis cell invasion and differentiation. Carcinogenesis. 2009; 30: 131-140.
  • 14
    Feng Y-Z, Showaza T, Miyamoto et al. Over expression of hedgehog signaling molecules and its involvement in the proliferation of endometrial carcinoma cells. Clin Cancer Res. 2007; 13: 1389-1398.
  • 15
    ten Haaf A, Bektas N, von Serenyi S, et al. Expression of the glioma-associated oncogene homolog (GLI) 1 in human breast cancer is associated with unfavorable overall survival [serial online]. BMC Cancer. 2009; 9: 298.
  • 16
    Hidalgo M. Pancreatic cancer. N Engl J Med. 2010; 362: 1605-1617.
  • 17
    Berman DM, Karhadkar SS, Maitra A, et al. Widespread requirement for hedgehog ligand stimulation in growth of digestive tract tumors. Nature. 2003; 431: 846-851.
  • 18
    Thayer SP, di Magliano MP, Heiser PW, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature. 2003; 425: 851-856.
  • 19
    Yauch RL, Gould SE, Scales SJ, et al. A paracrine requirement for hedgehog signaling in cancer. Nature. 2008; 455: 406-410.
  • 20
    Curran T, Hg JMY. Hedgehog's other trick. Nature. 2008; 455: 293-294.
  • 21
    Theunissen JW, de Sauvage FF. Paracrine hedgehog signaling in cancer. Cancer Res. 2009; 69: 6007-6010.
  • 22
    Wang G, Zhang Z, Xu Z. Activation of the sonic hedgehog signaling controls human pulmonary arterial smooth muscle cell proliferation in response to hypoxia. Biochim Biophys Acta. 2010; 1803: 1359-1367.
  • 23
    Bijlsma MF, Groot AP, Oduro JP, et al. Hypoxia induces a hedgehog response mediated by HIF-1alpha. J Cell Mol Med. 2009; 13( 8B): 2053-2060.
  • 24
    Onishi H, Kai M, Odate S, et al. Hypoxia activates the hedgehog signaling pathway in a ligand-independent manner by upregulation of Smo transcription in pancreatic cancer. Cancer Sci. 2011; 102: 1144-1150.
  • 25
    Rofstad EK, Sundfor K, Lyng H, Trope CG. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br J Cancer. 2010; 83: 354-359.
  • 26
    Fyles A, Milosevic M, Hedley D, et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol. 2002; 20: 680-687.
  • 27
    Milosevic M, Fyles A, Hedley D, et al. Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer Res. 2001; 61: 6400-6405.
  • 28
    Hockel M, Vorndran B, Schlenger K, Baussmann E, Knapstein PG. Tumor oxygenation: a new predictive parameter in locally advanced cancer of the uterine cervix. Gynecol Oncol. 1993; 51: 141-149.
  • 29
    Sims-Mourtada J, Izzo JG, Apiarnthanarax S, et al. Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. Clin Cancer Res. 2006; 12: 6565-6572.
  • 30
    Yoshikawa R, Nakano Y, Tao L, et al. Hedgehog signal activation in oesophageal cancer patients undergoing neoadjuvant chemoradiotherapy. Br J Cancer. 2008; 98: 1670-1674.
  • 31
    Chung C, Dignam JJ, Hammond EM, et al. Glioma-associated oncogene family zinc finger 1 expression and metastasis in patients with head and neck squamous cell carcinoma treated with radiation therapy (RTOG 9003). J Clin Oncol. 2011; 29: 1326-1334.
  • 32
    Hedley D, Pintilie M, Woo J, et al. Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas. Clin Cancer Res. 2001; 61: 639-6349.
  • 33
    Iakovlev VV, Pintilie M, Morrison A, Fyles AW, Hill RP, Hedley DW. Effect of distributional heterogeneity on the analysis of tumor hypoxia based on carbonic anhydrase IX. Lab Invest. 2007; 87: 1206-1217.
  • 34
    Hricak H, Gastonis C, Chi DS, et al. Role of imaging in pretreatment evaluation of early invasive cancer: results of the intergroup study American College of Radiology Imaging Network 6651-Gynecologic Oncology Group 183. J Clin Oncol. 2005; 23: 9329-9337.
  • 35
    Choi HJ, Kim SH, Seo SS, et al. MRI for pretreatment lymph node staging in uterine cervical cancer. AJR Am J Roentgenol. 2006; 187: W538-W543.
  • 36
    Fyles A, Milosevic M, Pintilie M, et al. Long-term performance of interstital fluid pressure and hypoxia as prognostic factors in cervix cancer. Radiother Oncol. 2006; 80: 132-137.
  • 37
    Bachtiary B, Boutros PC, Pintilie M, et al. Gene expression profiling in cervical cancer: an exploration of intratumor heterogeneity. Clin Cancer Res. 2006; 12: 5632-5640.
  • 38
    Dempter AP, Laird NM, Rubin DB. Maximum likelihood from incomplete data via EM algorithm. J R Stat Soc B. 1977; 39: 1-38.
  • 39
    Xuan YH, Soon Jung H, Coi Y-L, et al. Enhanced expression of hedgehog signaling molecules in squamous cell carcinoma of uterine cervix and its precursor lesions. Mod Pathol. 2006; 19: 1139-1147.
  • 40
    Pereira Tde A, Witek RP, Syn WK, et al. Viral factors induce hedgehog pathway activation in humans with viral hepatitis, cirrhosis, and hepatocellular carcinoma. Lab Invest. 2010; 90: 1690-1703.
  • 41
    Bendell JC, Hart LL, Firdaus I, et al. Safety analysis of a randomized phase II trial of hedgehog pathway inhibitor (HPI) GDC-0449 versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) [abstract]. J Clin Oncol. 2010; 28( 5S). Abstract 3530.